Beijing: Health authorities of the Republic of Peru have approved a Phase 3 clinical trial for a potential COVID-19 vaccine developed by China National Biotec Group (CNBG), the company said Thursday in Chinese social media platform Weibo.
The experimental vaccine of CNBG, a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), has already entered Phase 3 testing in United Arab Emirates.
Phase 3 trials, which usually involve several thousand participants, allow researchers to gather data on the efficacy of potential vaccines for final regulatory approvals.
The World Health Organization’s Europe office said it has begun discussions with Russia to try to obtain more information about the experimental COVID-19 vaccine the country recently approved.
Last week, Russia became the first country in the world to license a coronavirus vaccine when President Vladimir Putin announced its approval.
But the vaccine has not yet passed the advanced trials normally required to prove it works before being licensed, a major breach of scientific protocol.
Russian officials claimed the vaccine would provide lasting immunity to COVID-19 but offered no proof.
IANS
